FDA commissioner expected to resign amid policy disputes

# FDA Commissioner Makary Resigns Amid Policy Disputes

Dr. Marty Makary has resigned as commissioner of the Food and Drug Administration after just over a year leading the agency, stepping down amid internal conflicts over drug approvals and tobacco regulation. The departure comes after months of pressure from the White House and other administration officials over policy disagreements, particularly surrounding the FDA's approval of flavored e-cigarettes.

The immediate trigger for Makary's resignation centered on the FDA's May 6 approval of fruit-flavored vapes from Glas Inc. According to reports, Makary had resisted approving the flavored varieties but was ultimately forced to do so by other administration officials. The dispute highlighted broader tensions over the agency's regulatory direction, with conservative groups and anti-abortion activists also pressing Makary to take action on the abortion drug mifepristone. Kyle Diamantés is expected to assume the role of acting commissioner.

For Wisconsin residents, the leadership change at the FDA carries significant implications. The agency regulates one-fifth of all consumer spending in the United States, overseeing everything from prescription drugs and vaccines to tobacco products and food safety. Any shifts in the FDA's regulatory approach could affect the medications available to Milwaukee-area patients, the safety standards for products on store shelves, and how quickly new treatments reach the market.

The resignation comes as Congress debates broader reforms to the FDA's authority and oversight, raising questions about what direction the agency will take under new leadership and whether its regulatory standards will become more or less stringent.